Dietary curcumin supplementation attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in C57BL mice. 2015

Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150001 People's Republic of China ; Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi,Bunkyo-ku, Tokyo 113-8657, Japan.

Studies in vivo and in vitro suggest that curcumin is a neuroprotective agent. Experiments were conducted to determine whether dietary supplementation with curcumin has neuroprotective effects in a mouse model of Parkinson's disease (PD). Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) significantly induced the loss of dopaminergic cells in the substantia nigra and deletion of dopamine in the striatum, which was attenuated by long-term (7 weeks) dietary supplementation with curcumin at a concentration of 0.5% or 2.0% (w/w). Although curcumin did not prevent the MPTP-induced apoptosis of neuroblasts in the subventricular zone (SVZ), it promoted the regeneration of neuroblasts in the anterior part of the SVZ (SVZa) at 3 days after MPTP treatment. Furthermore, curcumin enhanced the MPTP-induced activation of microglia and astrocytes in the striatum and increased the expression of glial cell line-derived neurotrophic factor (GDNF) and transforming growth factor-β1 (TGFβ1) in the striatum and SVZ. GDNF and TGFβ1 are thought to play an important role in protecting neurons from injury in the central and peripheral nervous systems. These results suggest that long-term administration of curcumin blocks the neurotoxicity of MPTP in the nigrostriatal dopaminergic system of the mouse and that the neuroprotective effect might be correlated with the increased expression of GDNF and TGFβ1. Curcumin may be effective in preventing or slowing the progression of PD.

UI MeSH Term Description Entries

Related Publications

Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
November 2009, Molecular and cellular endocrinology,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
October 2001, Neuroscience letters,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
August 1986, Neuropharmacology,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
June 2003, Metabolic brain disease,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
March 1987, Life sciences,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
January 1985, Progress in neuro-psychopharmacology & biological psychiatry,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
December 1985, European journal of pharmacology,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
March 1991, Toxicology,
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
January 2019, Biomedical research (Tokyo, Japan),
Xi-Jun He, and Kazuyuki Uchida, and Chiaki Megumi, and Nobuaki Tsuge, and Hiroyuki Nakayama
August 1998, Neuroscience letters,
Copied contents to your clipboard!